Author

Wim Nerinckx

Ghent UniversityORCID 0000-0002-6563-8342Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1 Organism:rat· 1

Frequent Co-Authors

Annelies Van HeckeiD· 2 shared Bert SchepensiD· 2 shared Iebe RosseyiD· 2 shared Loes van SchieiD· 2 shared Nico CallewaertiD· 2 shared Sandrine VanmarckeiD· 2 shared Simon DevosiD· 2 shared Wander Van BreedamiD· 2 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMolecular Biology

Annelies Van HeckeORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

GlycoVHH: Introducing N-glycans on the camelid VHH antibody scaffold - Optimal sites and use for macrophage delivery

Loes van Schie, Wander Van Breedam, Charlotte Roels, Bert Schepens, Martin Frank, Ahmad Reza Mehdipour, Bram Laukens, Wim Nerinckx, Francis Santens, Simon Devos, Iebe Rossey, Karel Thooft, Sandrine Vanmarcke, Annelies Van Hecke, Xavier Saelens, Nico Callewaert

This study identifies optimal sites for introducing N-glycans on VHH antibodies to enhance macrophage delivery, demonstrating glycan-dependent uptake in vitro and in vivo.

mAbs · May 21, 2023Peer-reviewedMolecular Biology

Drug development of an affinity enhanced, broadly neutralizing heavy chain-only antibody that restricts SARS-CoV-2 in rodents

Bert Schepens, Loes van Schie, Wim Nerinckx, Kenny Roose, Wander Van Breedam, Daria Fijałkowska, Simon Devos, Wannes Weyts, Sieglinde De Cae, Sandrine Vanmarcke, Chiara Lonigro, Hannah Eeckhaut, Dries Van Herpe, Jimmy Borloo, ANDREZA ESTEFANY DA SILVA OLIVEIRA, , Xavier Saelens

The paper describes the development of a broadly neutralizing antibody, XVR011, effective against SARS-CoV-2 and its variants in animal models.

bioRxiv · Mar 8, 2021 · PreprintMolecular Biology